Who
Elizabeth A. Barrett
Director
Company insider
Files Form 4 as: Director, Allogene Therapeutics; Chief Executive Officer, UroGen Pharma; Director, Sage Therapeutics.
In numbers
- Trades disclosed
- 76
- Buys
- 4
- Sells
- 2
- Bought
- $645K
- Sold
- $492K
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 3 Jan 2018
- Last trade
- 18 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 23 Jun 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —95,400 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —95,400 at $0.00 | filing |
| 31 Jan 2026filed 19 Feb 2026 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —153,195 at $0.00 | filing |
| 31 Jan 2026filed 19 Feb 2026 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —153,195 at $0.00 | filing |
| 31 Jul 2025filed 31 Jul 2025 | Sage Therapeuticsoption or derivative | SEC FORM 4 Code D | —21,500 | filing |
| 31 Jul 2025filed 31 Jul 2025 | Sage Therapeutics | SEC FORM 4 Code U | —3,000 | filing |
| 28 Jul 2025filed 30 Jul 2025 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —87,615 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —95,400 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | Sage Therapeuticsoption or derivative | SEC FORM 4 Code A | —21,500 at $0.00 | filing |
| 31 Jan 2025filed 4 Feb 2025 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —96,377 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —191,082 at $0.00 | filing |
| 31 Jan 2024filed 2 Feb 2024 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —87,615 at $0.00 | filing |
| 13 Jun 2023filed 15 Jun 2023 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —116,120 at $0.00 | filing |
| 31 Jan 2023filed 2 Feb 2023 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 31 Jan 2023filed 2 Feb 2023 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —13,333 at $0.00 | filing |
| 31 Jan 2023filed 2 Feb 2023 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 31 Jan 2023filed 2 Feb 2023 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 31 Jan 2023filed 2 Feb 2023 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 31 Jan 2023filed 2 Feb 2023 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Code M | —5,000 | filing |
| 31 Jan 2023filed 2 Feb 2023 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Code M | —13,333 | filing |
News
Analyzing Urogen Pharma (NASDAQ:URGN) and Incannex Healthcare (NASDAQ:IXHL)URGN · themarketsdaily.com · 15 Oct 2026Reviewing Cronos Group (NASDAQ:CRON) and Urogen Pharma (NASDAQ:URGN)URGN · tickerreport.com · 13 Oct 2026
0 headlines in the last 90 days name Elizabeth A. Barrett; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.